Melanoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

7 of 7+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spain· EU contribution €150,000· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Light-triggered Ultra-precise Carbon-enhanced phycocyanin Engineered Needles for Therapy (LUCENT)

  Univerzita Palackeho V Olomouci· Olomouc, Czechia· EU contribution €191,918· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeted therapy to block melanoma progression through peptide phage-display profiling of melanoma cells and derived extracellular vesicles (Target-MelaneX)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugal· EU contribution €207,183· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  THz-FIR Colour Imaging of Skin Condition Based on Analysis of Its Thermal Emission (THz-Skin)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €2,998,913· until Jan 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Capturing UV Sunlight Using Hydrogen-Bond Networks: Organic Sun Screens for Skin Protection (CUSHOSP)

  United Nations Educational Scientific and Cultural Organization· Paris, France· EU contribution €150,000· until Jun 2027· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 12 running projects, newest first. Listed amounts together: €11.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors.

  Oncologist, Oct 2026

• Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01).

  Cancer Res Commun, Oct 2026

• Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey.

  Eur J Cancer, Sept 2026

• Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma.

  J Transl Med, Sept 2026

• Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology.

  Acta Oncol, Sept 2026

• Longitudinal BRAF ctDNA monitoring in melanoma reflects disease status and predicts relapse.

  J Dermatol Sci, Jul 2026

• Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy.

  Am J Clin Dermatol, Jul 2026

• Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR.

  Mol Diagn Ther, Jul 2026

• The role of circulating tumor DNA in the management of melanoma: a literature review.

  Melanoma Res, Jun 2026

• Predictive value of serum biomarkers for survival in melanoma: a systematic review and meta-analysis.

  Sci Rep, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.